HAVIA
HAVIA BIO creates long‑acting therapeutics that boost the body’s natural healing and regeneration processes. Their platform uses HYALUTE™ microparticle technology to form a sustained hyaluronic acid matrix for localized drug delivery, aiming to increase efficacy while reducing the frequency of treatments.
- Biotechnology
Funding
Founders
Product
Problem
Many chronic diseases require frequent drug administrations to maintain therapeutic levels, leading to patient burden, reduced adherence, and increased healthcare costs. Conventional delivery methods often provide only short-lived exposure, limiting efficacy in conditions that need sustained tissue support and regeneration.
Solution
Havia Bio develops long‑acting therapeutics that create a localized, sustained hyaluronic acid (HA) matrix using its proprietary HYALUTE™ microparticle technology. The HA matrix serves as a scaffold that continuously releases the active drug at the target site, enhancing therapeutic efficacy while decreasing the number of required treatments. By extending the duration of drug exposure and supporting tissue regeneration, the platform aims to improve outcomes for chronic conditions where ongoing tissue support is critical. The approach leverages biocompatible HA to minimize systemic side effects and simplify dosing regimens.
Target Audience
Primary customers are pharmaceutical and biotech companies developing therapies for chronic musculoskeletal, ophthalmic, and regenerative medicine indications that benefit from sustained local drug delivery.
Features
- HYALUTE™ microparticles form an in situ HA matrix that provides continuous, localized drug release
- Controlled release kinetics extend therapeutic exposure from weeks to months
- Biocompatible hyaluronic acid scaffold supports tissue regeneration and reduces inflammation
- Platform-agnostic design enables incorporation of diverse small‑molecule and biologic agents
- Reduced dosing frequency improves patient adherence and lowers overall treatment costs